Loading...
|
Please use this identifier to cite or link to this item:
https://ir.csmu.edu.tw:8080/ir/handle/310902500/22201
|
| Title: | Early Seroreversion After 2 Doses of Hepatitis A Vaccination in Human Immunodeficiency Virus-Positive Patients: Incidence and Associated Factors |
| Authors: | Huang, Sung-Hsi;Huang, Chung-Hao;Wang, Ning-Chi;Chen, Tun-Chieh;Lee, Yuan-Ti;Lin, Shih-Ping;Lin, Te-Yu;Lin, Chi-Ying;Lee, Yu-Lin;Lee, Chen-Hsiang;Chen, Cheng-Pin;Lin, Kuan-Yin;Chen, Guan-Jhou;Liu, Chun-Eng;Cheng, Shu-Hsing;Lu, Po-Liang;Yang, Chia-Jui;Hung, Chien-Ching;Group, Taiwan HIV Study |
| Contributors: | 中山醫學大學;醫研所 |
| Date: | 2019-01-07 |
| Issue Date: | 2022-03-29T03:13:37Z (UTC)
|
| Publisher: | AASLD |
| Abstract: | Serological responses (Seroresponse) and durability of hepatitis A virus (HAV) vaccination are reduced among human immunodeficiency virus (HIV)-positive patients. Incidence of and associated factors with early seroreversion (loss of seroresponse) among HIV-positive patients who have achieved seroresponses after two doses of HAV vaccination remain unclear. In this multicenter study, we followed HIV-positive adults who had mounted seroresponses after completing two doses of HAV vaccination during a recent outbreak of acute hepatitis A between 2015 and 2017, a 1:4 case-control study was conducted to identify factors associated with seroreversion. Case patients were those with seroreversion, and controls were those with similar follow-up durations who were able to maintain seroresponses. During the study period, 49 of the 1,256 patients (3.9%) seroreverted after a median follow-up of 611 days. In a case-control study, seroreversion was more likely to occur in patients with a higher weight (adjusted odds ratio [aOR], 1.703; 95% confidence interval [CI], 1.292-2.323, per 10-kg increment) and HIV viremia at the time of vaccination (aOR, 2.922; 95% CI, 1.067-7.924), whereas positive seroresponse at 6 months of HAV vaccination and higher CD4 lymphocyte counts at vaccination were inversely associated with early seroreversion with an aOR of 0.059 (95% CI, 0.020-0.154) and 0.837 (95% CI, 0.704-0.979, per 100-cell/mm3 increment), respectively, in multivariable analyses. Conclusion: During an outbreak setting, early seroreversion following two-dose HAV vaccination occurred in 3.9% of HIV-positive patients. Lower and delayed seroresponses to HAV vaccination, a higher weight, and HIV viremia and lower CD4 lymphocyte counts at the time of HAV vaccination were associated with early seroreversion. Regular monitoring of seroresponse and booster vaccination might be warranted, especially in HIV-positive adults with predictors of early seroreversion. |
| URI: | https://ir.csmu.edu.tw:8080/handle/310902500/22201 |
| Relation: | Hepatology, 70(2), 465-475 |
| Appears in Collections: | [醫學研究所] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| Hepatology - 2019 - Huang - Early Seroreversion After 2 Doses of Hepatitis A Vaccination in Human Immunodeficiency Virus.pdf | | 486Kb | Adobe PDF | 159 | View/Open |
|
All items in CSMUIR are protected by copyright, with all rights reserved.
|
